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Reply
Sir,
We thank Jean-Pierre Wauters and colleagues for their
helpful comments. The lower level of cyclosporin A (CsA)
under sevelamer may indeed be due to a direct binding of
CsA by sevelamer, rather than to an indirect impact of
sevelamer on bile acids. Thus, the recommendation of a delay
between the intake of sevelamer and that of drugs such as
CsA is fully warranted. We disagree, however, on the claim
that calcium-based binding is fully speciﬁc for phosphate.
Indeed, the co-administration of either calcium acetate or
sevelamer with ciproﬂoxacin recently has been shown to
reduce the oral bioavailability of the latter drug by some 50%
[1].
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Sevelamer and pharmacokinetics of cyclosporin A
after kidney transplantation
Sir,
In their interesting article, Pieper et al. analysed prospectively
the effect of sevelamer on the pharmacokinetics of cyclo-
sporin (CsA) and mycophenolate mofetil (MMF) in kidney
transplanted patients [1]. They provide the reassuring
message that, in contrast to MMF, CsA kinetics are not
signiﬁcantly modiﬁed by the intake of sevelamer. These
results are in sharp contrast to the observation and potential
mechanisms that we reported recently [2,3].
The short duration (4 days) and limited statistical power
(10 adults and eight children) of the study of Pieper et al.
make such a strong message rather questionable [4]. Indeed,
only 4 days after starting sevelamer, none of the CsA
parameters (measured by Cedia and FPIA assays) was
completely stable: the area under the curve (AUC) decreased
from 3547±660 to 3230±612 ng/h/ml, Cmax decreased from
955±193 to 855±272 ng/ml and Tmax increased from 1.3
to 1.5 h. In addition, when measured with polyclonal anti-
bodies, the CsA levels decreased signiﬁcantly and, among
its primary metabolites determined by HPLC, the AUC and
Cmax of AM1—which also has an immunosuppressive action
[5]—decreased signiﬁcantly by 30 and 25%, respectively.
Despite these observations, the authors conclude that
‘sevelamer intake for several days does not signiﬁcantly
inﬂuence CsA kinetics’. Based on their data, this conclusion
appears at least premature, especially if the risk of transplant
rejection due to insufﬁcient immunosuppression is considered
[6]. Great caution in the use of sevelamer in transplanted
patients is still warranted until a careful long-term, large
size study on the potential interaction of sevelamer with CsA
solves the question.
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